The best donors for hematopoietic SCT (HSCT) are fully-matched siblings. In patients without fully-matched siblings, HLA registries or cord blood banks are alternative strategies with some restrictions. Owing to the high rate of consanguineous marriage in our country, between 2006 and 2013, extended family searches were undertaken in Hematology-Oncology Research Center and Stem Cell Transplantation (HORCSCT), Tehran, Iran, in 523 HSCT candidates with parental consanguinity and no available HLA identical sibling. Fully-matched other-relative donors were found for 109 cases. We retrospectively studied the HSCT outcome in these patients. Median time to neutrophil engraftment was 13 days (range: 9-31days). In 83 patients, full chimerism and in 17 patients, mixed chimerism was achieved. Acute GvHD (aGvHD) grade II-IV appeared in 36 patients (33%). The frequency of aGvHD development in various familial subgroups was NS. Five patients expired before day+100. In the surviving 104 cases, chronic GvHD developed in 20 patients (19.2%). The distantly related subgroup had significantly a higher rate of cGvHD (P = 0.04). The 2-year OS and disease-free survival (DFS) were 76.7 ± 4.5% and 71.7 ± 4.7%, respectively. No significant difference in OS (P = 0.30) and DFS (P = 0.80) was unraveled between various familial relationships. Our considerable rate of fully-matched non-sibling family members and the favorable outcome support the rationale for extended family search in regions where consanguineous marriage is widely practiced.
INTRODUCTION
At the present time, treatment of a wide spectrum of malignant and non-malignant diseases is accomplished by allogeneic hematopoietic SCT (HSCT) as a rapidly advancing procedure. 1, 2 However, the best donors have been presented as fully-matched siblings; [1] [2] [3] [4] [5] [6] unfortunately, the probability of finding fully-matched siblings is approximately between 25 and 30%. 1, 3, 5, [7] [8] [9] [10] During the recent three decades, efforts have been exerted to find unrelated donors for those lacking fully-matched sibling donors by means of establishing HLA registries or umbilical cord blood banks, 6, 8, 10 each having its own pros and cons. 11, 12 Although transplantation from unrelated donors through HLA registries has saved many lives till now and its outcome has been found virtually the same as transplantation from related donors, 13, 14 efficacy of such transplantations is still less than related ones. 14, 15 The lengthy period of national and international search [16] [17] [18] when required and the financial burden of this process 19 are considered as the significant limitations. Cord blood banks are being established as another alternative strategy to reach unrelated donors to undertake transplants. 19 However, owing to high expense, its application is not an option for many patients of low-income strata. Additionally, as the cell number and volume of cord bloods are limited, these transplants would be exclusive for low-weighting patients. 20 The remarkable problem that must be considered is that the HLA registries and cord blood banks do not exist in many countries, particularly in a developing subcontinent, or they act with limited capacity. 21 On the other hand, some developing countries facing economical problems do benefit from interrelative marriages that provide them with an extent and available family bank. In the case of consanguinity in relative marriages in the patient family, the probability of finding fully-matched otherrelated donor will be increased. 22 Since the year 2006 in which Pediatric stem cell transplantation Unit was established in Hematology/Oncology research center and stem cell transplantation (HORCSCT), because of the lack of HLA registry in that period of time in our country and also insufficiency of cord samples stored in public cord blood banks and on the other hand regarding to the high rate of inter-relative marriages in our country, it was decided to carry out extended searches in patient's families to find fully-matched donors. This process was intended to be carried out for all HSCT candidate children and adults with consanguineous parents. As a limited number of reports about the other-related transplantation results already exist, we aimed to perform a precise survey of the outcome of such transplantations in our center.
PATIENTS AND METHODS

Patients' enrollment
Between November 2006 and January 2013, 1270 of patients who referred to HORCSCT, Tehran, Iran for allogeneic HSCT and did not have any available HLA-matched sibling, were enrolled. Of this number, 523 cases had parental consanguinity (194 marriages were between first cousins).
Hence, their family profile (including father, mother, grandparents, aunts, uncles, etc) was extracted and drawn, and an extended family search was undertaken. On average, for each of the 523 cases, HLA typing was conducted in eight of other relatives (range: 2-24 individuals). On the basis of the algorithm strategy, first the parents were examined, secondly aunts and uncles, and thirdly grandparents were tested. After investigation of the biologic pedigree, if the immunologist denoted the possibility of finding a full-match in other distant relatives, the search was extended to that domain. The search would be halted at each step in case a matched donor was found. It is noteworthy that at the primary stage, low-resolution typing was performed for HLA A, HLA-B, HLA-C and HLA-DRB1. After finding a primary match, the process was ensued via high-resolution typing to reach confirmatory results.
Alleles A,B, C and DRB1 are inherited collectively from parents and the pattern of these alleles is similar in family members. Therefore, the HLAmatching process was ensued up to 8/8 full-match was obtained. The level was acceptable based on the protocol applied at our center. Additionally, numerous studies in unrelated donors has postulated the 8/8 matching level as acceptable.
On the basis of this protocol, fully-matched other relative donors were found for 109 of cases (20.8%). We retrospectively studied the transplantation outcome in these patients.
The primary diagnosis of such patients was made by the referral institutions where they received their initial treatments; thereafter, the disease diagnosis was further assessed and confirmed in HORCSCT. Table 1 summarizes the characteristics of patients and donors as well as the conditioning regimens used.
Transplantation characteristics
BM stem cells (BMSCs) and PB stem cells (PBSCs) were utilized for HSCT procedure. BMSCs collection was the preferential method. However, in case the donor's medical condition was not appropriate or the donor did not give consent for BMSC collection procedure, PBSCs were collected. BMSCs were collected by standard techniques from the donor on the day of infusion. On the other hand, PBSC donors received G-CSF 5 μg/kg per day from day − 4 to day − 2. On day − 1, G-CSF dose was increased to 10 μg/kg per day. On day 0, stem cell extraction process was performed.
Supportive care
During admission in the transplant unit, patients received similar supportive care. Acyclovir was administered for Herpes Simplex and Varicella Zoster virus prophylaxis. Trimethoprim-sulfamethoxazole was also prescribed as prophylactic agent for Pneumocystis jiroveci. In addition, fluconazole or itraconazole was given for fungal infection prophylaxis. Tests for CMV PP65 Ag or CMV DNA PCR were performed twice weekly. Positive cases for CMV went under treatment by Ganciclovir for either 21 days or until the infection subsided. Complementary care as for blood transfusion or parenteral nutrition was also provided.
Moreover, patients were monitored for potential post transplant adverse events such as hemorrhagic cystitis and veno-occlusive disease.
Follow-up
After being discharged, follow-up schedule was pursued on a weekly basis until day +90. For the next 2 months, visits were conducted every other week and thereafter on monthly basis till 1 year post transplant. Afterwards, on the basis of each patient's status, the visits were set.
Hematopoietic chimerism monitoring was performed via STR or FISH at regular intervals on days +15, +30, +60, +90 and +180. Chimerism was further evaluated on 12th, 18th and 24th months after transplantation and annually, thereafter.
Definitions
Neutrophil engraftment was defined as the first three consecutive days with ANC exceeding 500/μL threshold without G-CSF support. Platelet engraftment was defined as the first seven consecutive days without transfusion with platelet count of 420 000/μL. 23 Furthermore, patients were examined and classified for acute GvHD (aGvHD) and chronic GvHD (cGvHD) according to the standard criteria 24, 25 and treated afterwards. Patients surpassing 100 days were evaluated for cGvHD.
Patients who demonstrated chimerism of more than 95% were considered as full chimerism, while chimerism in the range of 5-95% was stratified as mixed chimerism and less than 5% indicated rejection. Abbreviations: ATG = anti-thymocyte globulin; FEL = familial erythrophagocytic lymphohistiocytosis; IEM = inborn errors of metabolism; LAD = leukocyte adhesion deficiency; MIOP = malignant infantile osteopetrosis; MLD = metachromatic leukodystrophy; MNC = mononuclear cell; MPS = mucopolysaccharidosis; PID = primary immunodeficiencies.
Disease-free survival (DFS) was defined as time interval between the transplantation and the date of relapse, death or the last contact. OS was defined as the time interval from HSCT to death. Patients without experiencing event were considered as censored observations.
Statistical analysis
AGvHD frequencies were compared among groups using chi-square test. Cumulative incidence function was used to express cGvHD incidence in competing risks setting and death before cGvHD was regarded as its competing event. OS and DFS probabilities were estimated using KaplanMeier curves and were compared between groups through log-rank test. Cumulative incidences of disease recurrence and TRM were compared using Gray's test in a competing risks setting. When P-values were less than 0.05, the results were considered statistically significant. All of the analyses were performed via SPSS software version 21 (SPSS, Chicago, IL, USA) and 'cmprsk' package in R software version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria, 2014, www.R-project.org).
RESULTS
Patients and donors characteristics
A total of 109 patients entered our study, consisting of 69 males (64%) and 40 females (36%). The median age of recipients was 8 years (range, 4 months to 55 years) at the time of transplantation. The median age of donors was 36 years (range, 9-73 years). The largest age gap between donor and recipient was that of a 1-year-old case of leukocyte adhesion deficiency and his 73-year-old grandfather. It is noteworthy that because of the relative ties, the donors were absolutely sympathetic and cooperative. Similar to donor recruitment from siblings, the other relatives participated in the stem cell collection process readily with minimum of delay. The time interval from diagnosis to transplant was shorter than 45 days in all cases.
The patients' diseases comprised malignant and non-malignant types. Table 1 summarizes the characteristics of patients and donors as well as the conditioning regimens used. The distantly related subgroup had the highest percentage of malignancies (62.5%) while the father subgroup had the lowest (16.0%).
The distribution of diseases in various subgroups is summarized in Table 2 .
Infused cells and engraftment Seventy-two cases (66.1%) received BMSC and 37 patients (33.9%) underwent PBSC transplantation. Mothers constituted the majority of BMSC donors (40.3%). In 51 cases (46.8%), donor and recipient's blood groups were matched. Median time to neutrophil engraftment was 13 days (range, 9-31days), whereas Median time to platelet engraftment was 18 (range, 14-43) days. In 83 patients (76.1%), full chimerism was achieved. Seventeen patients (15.6%) had mixed chimerism and nine patients (8.3%) experienced rejection.
Graft versus host disease (GvHD) According to our data, aGvHD appeared in 57 patients (52.3%). To compare aGvHD, patients were stratified in two subgroups: Grade 0-I and grade II-IV. Seventy-three cases (67.0%) fell into grade 0 or I subgroup. On the other hand, 36 cases (33.0%) had grade II-IV aGvHD. HSCT recipients from grandparents and distantly related donors had the lowest incidence of grade II-IV aGvHD, whereas recipients from aunts/uncles had the highest rate of this category of aGvHD. The distribution of aGvHD among various subgroups did not show any significant difference (P-value = 0.3) ( Table 3) .
Five patients expired before day +100 post transplant (4 cases because of GvHD and 1 because of infection). In the surviving 104 cases, Gray's test was applied to compare cumulative incidence of cGvHD (P-value = 0.14) ( Table 4 ). CGvHD developed in 20 patients (19.2%) including 10 limited and 10 extended cGvHD types. In patients who received the transplant from their fathers, no cGvHD was detected (P-value = 0.04). On the other hand, recipients from distantly related donors experienced the highest rate of cGvHD (P-value = 0.04). The aunt/uncle subset of patients demonstrated the highest rate of extended cGvHD (15.4%) whereas the grandparents subset had the highest prevalence of limited cGvHD (16.7%). However, the distribution of limited and extended cGvHD did not show a significant difference (P-value = 0.114) ( Table 3) . It is noteworthy that in 75% of grandparent donors (9 out of total 12 cases), PBSC was the source. Both aGvHD (P-value = 0.02) and cGvHD (P-value = 0.01) more commonly developed in the PBSC group in comparison with BMSC recipients.
Post transplantation complications
Post transplant complications were noted in 19 patients (17.4%) whereas no complications were detected in the remaining 90 patients (82.6%). Seizure was the most common side effect which was observed in seven cases (36.8% of total post transplantation complications). The distribution of complications between various subgroups did not show significant differences (P-value = 0.34).
Transplant outcome
The median duration of follow-up was 24.6 months (range, 6-44 months). At the end of our study, 84 patients were still alive. During the follow up period, 31 patients (28.4%) experienced the recurrence of disease including relapse in 10 malignant cases. Median time to disease recurrence was 80 days after transplantation. Twenty-five patients (22.9%) expired during follow-up period. GvHD was the most common cause of death, which was implicated in eight patients (32.0%). Other notable causes of death comprised of infection, relapse and transplant rejection (Table 4) .
Overall and disease-free survival On the basis of our study, the 2-year OS and DFS were 76.7 ± 4.5% and 71.7 ± 4.7%, respectively. Donor-recipient-matched blood groups, BMSC source of progenitor cells and non-malignant underlying pathologies were associated with better outcome. However, analysis of OS and DFS criteria based on single variables, unraveled no significant association (Table 5) . Figures 1a-d show the 2-year OS and DFS plots based on underlying diseases and donor-recipient relation.
Cumulative incidence of relapse and TRM were compared via cumulative incidence function test. No significant difference in cumulative incidence of relapse (P-value = 0.804) and TRM (P-value = 0.365) were detected between various non-sibling subgroups. However, the comparison between sex-matched and -mismatched strata demonstrated significant difference with mismatched subset featuring lower TRM (P-value = 0.033). The cumulative incidence function test results are tabulated in Table 6 .
Furthermore, we collectively compared OS and DFS in transplantation from parents versus other donor subgroups (non-parents). The analysis revealed no significant difference in OS (P-value = 0.4) and DFS (P-value = 0.613) between these two subgroups ( Table 7) .
DISCUSSION
The optimal donors regarding HSCT process are fully-matched siblings. The study by Ottinger et al. 26 has reported up to 40% of transplant candidates in North America and Europe finally find a fully-matched sibling. However, in some regions such as the Eastern Mediterranean region, the chances of finding a fullymatched sibling increase proportionately to family size and intracommunity ties. 27 Interestingly, studies in countries in the Middle East such as Saudi Arabia and Pakistan have unraveled the higher likelihood of finding a fully-matched sibling in comparison with North America or Europe. 28, 29 Owing to the scarcity of non-sibling application in the routine process of transplantation, we aimed to present a preliminary report on the general perspective of this strategy and the outcome in our studied cohort.
Alternative strategies such as cord blood banks or HLA registries have been proposed to obtain matched unrelated donors. 23 These strategies bear a number of substantive tribulations including donor attrition, lengthy process and high expenses. 24 Moreover, in developing countries, infrastructures such as HLA registries and cord blood banks are sparsely distributed and underperforming specifically for pediatric patients or ethnic minorities. 25 These logistic and socioeconomic obstacles impede timely donor recruitment. Of note, some studies have reported Abbreviations: BMSC = BM stem cell; DFS = disease-free survival; PBSC = PB stem cell.
that HSCT from unrelated donors is associated with a higher rate of TRM. [30] [31] [32] [33] Parental consanguinity has been implicated in numerous congenital disorders because of a higher possibility of recessive gene expression. 34, 35 In some regions, these trends of marriage constitute as much as 30% of all marriages. 36 Moreover, the surveys have indicated that the rate of consanguineous marriages is escalating in some Asian countries. 36 This incremental pattern may be due to domineering socio-cultural background in these geographic regions. 34 The considerable rate of consanguineous marriage along with its considerable risk of genetic disorders enhances the chance to find a fully-matched individual through extended family search. Therefore, the extended family search is a more practical method to find donors in regions where consanguineous marriage is more frequently practiced. 22, 37 Klein et al. 37 reported family search was considerably more successful in finding HLA-identical donors in Arabic patients in comparison with Jewish subpopulation. This difference resulted from large size of family and higher rate of consanguineous marriages in Arabic society. 37 According to our results, transplant outcome was comparable among various other relative donor types. OS ranged between 62.5 and 100% and DFS was in the 62.5-78.2% bracket. AGvHD and cGvHD rates ranged between 43.2% and 87.5% and 0% and 28.6%, respectively. In the malignant subset, the transplant outcome was similar to other studies applying fully-matched sibling donors. 13, [38] [39] [40] [41] Furthermore, OS and DFS in the nonmalignant subset including Thalassemia and severe aplastic anemia cases were comparable with other studies of allogeneic transplantation from sibling donors. 40, [42] [43] [44] [45] [46] The overall rates of aGvHD and cGvHD in both malignant and non-malignant subsets were comparable with other studies applying sibling donors. [47] [48] [49] [50] As one might predict, PBSC was accompanied with higher risk of cGvHD and aGvHD. Full and mixed chimerism was noted in 76% and 15% of recipients, respectively, while in 8% of patients, rejection occurred. The overall outlook of chimerism results was comparable with other studies applying sibling donors. [51] [52] [53] [54] Regarding the recent studies, outcomes of matched-other related HSCT in our study are comparable with matched-sibling donors. 47, 55, 56 It is noteworthy that our patients were mostly pediatric cases. The age factor may justify the overall favorable outcome of the transplant. Furthermore, the majority of patients had received anti-thymocyte globulin with conditioning chemotherapy. Previous studies have indicated the significant role of this combination therapy in survival of patients. 57 Hence, antithymocyte globulin administration may have partially contributed to the better outcome. In addition, distribution of malignant and non-malignant cases may have affected the OS and TRM Cumulative probability of survival rates. The distantly related subgroup had the highest rate of malignancies which may be implicated in the poor OS and higher TRM of this subgroup. Taken together, in societies where consanguineous marriage is widely practiced, study of the extended family should be regarded as an integral part of donor selection process. This extensive search should precede seeking cord blood banks and HLA registries as a time-saving cost-effective alternative strategy. 37, [42] [43] [44] 46, [58] [59] [60] Our considerable rate of fully-matched non-sibling family members (109 out of 523 cases) supports the rationale to routinely conduct extended family search. Future prospective multicenter studies with expanded sample size are warranted to compare other relative donors with siblings or unrelated donors. Abbreviations: BMSC = BM stem cell; CI = confidence interval; CIR = cumulative incidence of relapse; PBSC = PB stem cell. 
